SIMCERE PHARMAC. GRP LTD (S2P) - Total Assets
Based on the latest financial reports, SIMCERE PHARMAC. GRP LTD (S2P) holds total assets worth €14.73 Billion EUR (≈ $17.22 Billion USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See SIMCERE PHARMAC. GRP LTD shareholders equity for net asset value and shareholders' equity analysis.
SIMCERE PHARMAC. GRP LTD - Total Assets Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's total assets have evolved over time, based on quarterly financial data. Check SIMCERE PHARMAC. GRP LTD (S2P) asset resilience to evaluate the company's liquid asset resilience ratio.
SIMCERE PHARMAC. GRP LTD - Asset Composition Analysis
Current Asset Composition (December 2025)
SIMCERE PHARMAC. GRP LTD's total assets of €14.73 Billion consist of 50.2% current assets and 49.8% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 23.9% |
| Accounts Receivable | €2.49 Billion | 16.9% |
| Inventory | €589.50 Million | 4.0% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €1.44 Billion | 9.8% |
| Goodwill | €142.47 Million | 1.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how SIMCERE PHARMAC. GRP LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see S2P market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: SIMCERE PHARMAC. GRP LTD's current assets represent 50.2% of total assets in 2025, an increase from 49.0% in 2021.
- Cash Position: Cash and equivalents constituted 23.9% of total assets in 2025, up from 9.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 9.0% of total assets, an increase from 1.0% in 2021.
- Asset Diversification: The largest asset category is accounts receivable at 16.9% of total assets.
SIMCERE PHARMAC. GRP LTD Competitors by Total Assets
Key competitors of SIMCERE PHARMAC. GRP LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
GALDERMA GROUP AG
NYSE:GALDY
|
USA | $13.39 Billion |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Ajanta Pharma Limited
NSE:AJANTPHARM
|
India | Rs56.72 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Guizhou Bailing Group Pharmaceutical Co Ltd
SHE:002424
|
China | CN¥5.95 Billion |
SIMCERE PHARMAC. GRP LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.21 | 2.01 | 2.10 |
| Quick Ratio | 2.03 | 1.80 | 1.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €4.04 Billion | €2.76 Billion | €3.36 Billion |
SIMCERE PHARMAC. GRP LTD - Advanced Valuation Insights
This section examines the relationship between SIMCERE PHARMAC. GRP LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.76 |
| Latest Market Cap to Assets Ratio | 0.22 |
| Asset Growth Rate (YoY) | 27.9% |
| Total Assets | €14.73 Billion |
| Market Capitalization | $3.17 Billion USD |
Valuation Analysis
Below Book Valuation: The market values SIMCERE PHARMAC. GRP LTD's assets below their book value (0.22x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: SIMCERE PHARMAC. GRP LTD's assets grew by 27.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for SIMCERE PHARMAC. GRP LTD (2021–2025)
The table below shows the annual total assets of SIMCERE PHARMAC. GRP LTD from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €14.73 Billion ≈ $17.22 Billion |
+27.94% |
| 2024-12-31 | €11.51 Billion ≈ $13.46 Billion |
+6.05% |
| 2023-12-31 | €10.85 Billion ≈ $12.69 Billion |
+0.60% |
| 2022-12-31 | €10.79 Billion ≈ $12.61 Billion |
+6.18% |
| 2021-12-31 | €10.16 Billion ≈ $11.88 Billion |
-- |
About SIMCERE PHARMAC. GRP LTD
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China. The company focuses on various therapeutic areas, including oncology, central nervous system, autoimmune, anti-infection, cardiovascular, and others. Its princi… Read more